Washington – President Donald Trump is expected to announce Dr. Heidi Overton as his next Food and Drug Administration (FDA) commissioner, according to a source familiar with the decision. The move would place a trusted member of the administration at the helm of an agency that has faced intense scrutiny and operational challenges over the past year.
Background on the nomination
Dr. Overton currently serves as deputy director of the White House Domestic Policy Council, where she has helped shape the administration’s health‑care agenda. Prior to that role, she spent time in the first Trump White House and later joined the conservative America First Policy Institute, overseeing its health policy center. Her medical training and policy experience position her as a bridge between clinical expertise and the administration’s regulatory priorities.
Recent turnover at the FDA
The upcoming nomination follows the resignation of Dr. Marty Makary, who stepped down as FDA commissioner after roughly three months in the post. Makary’s departure was attributed to mounting pressure from the White House over his management of the agency, including disagreements on drug‑approval timelines and public‑health messaging.
Implications for the agency
Industry observers note that Dr. Overton’s appointment could signal a shift toward a more streamlined regulatory approach, consistent with the administration’s broader health‑policy goals. The FDA has been navigating a complex landscape that includes the approval of novel therapies, pandemic‑related vaccine distribution, and ongoing debates over food safety standards.
Critics of the administration have warned that a politically aligned commissioner may prioritize ideological goals over scientific independence. Supporters, however, argue that Overton’s experience within the Domestic Policy Council will enable more efficient coordination between the FDA and other federal health agencies.
What comes next
Should the nomination be confirmed by the Senate, Dr. Overton would inherit an agency tasked with safeguarding the nation’s food supply, overseeing the approval of pharmaceuticals, and regulating medical devices. The confirmation process is expected to involve hearings before the Senate Health, Education, Labor and Pensions Committee, where senators will likely question her views on drug pricing, vaccine policy, and the balance between regulatory rigor and market access.
The White House has not yet responded to requests for comment on the pending nomination. The story remains developing, and further details will be added as they become available.
Original reporting: KEYT (Ventura/Santa Barbara) — read the source article.
